Glaxo News
- Glaxo has launched its Diskus multi-dose powder drug delivery system for asthmatics in Sweden and Norway. The product, which has a provisional tradename of Accuhaler in some markets, will be launched as a delivery system for Serevent (salmeterol) and Flixotide (fluticasone propionate). The initial launch is for the Serevent Accuhaler. During the year, Glaxo expects the product to be launched in 15 to 20 countries. Meantime, Nippon Glaxo, the company's Japanese subsidiary, has received a positive decision from a Tokyo district court regarding patent infringement by Sakai Yakhuin, Taisho Pharm and Choseido Pharm of its Japanese ranitidine patents. All three firms were issued with injunctions to prevent further generic production.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze